益血生胶囊联合西药治疗慢性丙型病毒性肝炎40例临床观察  

Clinical Observation on Yixuesheng Capsule( 益血生胶囊) Combined with Western Medicine Treating 40 Cases of Chronic Viral Hepatitis C

作　　者：梁惠卿[1,2] 吴耀南[2] 杨嘉恩[2] 唐金模[2] 陈少东[1] 林莉[2] 

机构地区：[1]厦门大学医学院 [2]厦门市中医院

出　　处：《中医杂志》2015年第16期1394-1397,共4页Journal of Traditional Chinese Medicine

基　　金：福建省卫生厅青年科研课题(2012-2-105)

摘　　要：目的观察益血生胶囊联合聚乙二醇化干扰素α-2a(PEG-IFNα-2a)、利巴韦林片治疗慢性丙型病毒性肝炎的临床疗效。方法 80例慢性丙型病毒性肝炎患者采用随机数字表法分为治疗组和对照组各40例,均给予PEG-IFNα-2a(每次180μg,皮下注射,每周1次)以及利巴韦林片(每次300 mg,口服,每天3次)治疗,疗程6个月。治疗组在此治疗的首3个月,加用益血生胶囊口服,每次1 g,每天3次。两组患者治疗结束后随访6个月。观察治疗前后两组患者血清丙氨酸氨基转移酶水平、丙型肝炎病毒定量、中性粒细胞计数、血红蛋白含量、血小板计数的变化,比较两组患者生化学应答及病毒学应答百分比及骨髓抑制发生率。结果两组患者治疗3、6个月及随访6个月时病毒学应答比较差异均无统计学意义(P>0.05);两组患者治疗6个月及随访6个月生化学应答比较差异亦无统计学意义(P>0.05);治疗3、6个月时,治疗组的骨髓抑制发生率分别为35.00%及22.50%,均低于对照组的80.00%与60.00%(P<0.01)。结论伍用益血生胶囊可减少PEG-IFNα2a、利巴韦林片治疗慢性丙型病毒性肝炎患者的骨髓抑制作用,但未能提高抗病毒疗效。Objective To observe the clinical effect of Yixuesheng Jiaonang combined with pegylated interferonα-2a （PEG-IFNα-2a） and ribavirin on viral hepatitis C （CHC）. Methods According to random number table, 80 patients with CHC were divided into treatment group of 40 cases and control group of 40 cases. Both groups were given PEG-IFNα-2a （180μg each time, subcutaneous injection, once a week） and ribavirin （300mg each time, oral administration, three times a day） for 6 months. In the first 3 months, treatment group was added with Yixuesheng Jiaonang orally （ 1 g each time, 3 times a day）. After treatment, both groups were followed up for 6 months. Changes of patients＇ serum Alanine amino transaminase （ALT）, quantity of hepatitis C virus, neutrophil count, hemoglobin content and platelet count were observed before and after treatment. Patients＇ percentage of biochemical and virological responses and incidence of myelosuppression were compared. Results There was no significant difference in virological responses between the two groups in the 3rd and 6th month of treatment and the 6th month of following up （P 〉 0. 05）. There was also no significant difference in biochemical responses between the two groups in the 6th month of treatment and the 6th month of following up （P 〉 0. 05 ）. In the 3rd and 6th month of treatment, the incidence of myelosuppression in treatment group was 35.00% and 22. 50%, respectively, both of which were lower than that in control group （ 80.00% and 60. 00%, P 〈 0.01 ）. Conclusion Combined with Yixuesheng Jiaonang, the effect of myelosuppression of PEG-IFNα2a and ribavirin treating CHC is attenuated, but the antiviral effect is not improved.

关 键 词：慢性丙型病毒性肝炎 干扰素Α 利巴韦林 益血生胶囊 骨髓抑制 

分 类 号：R512.63[医药卫生—内科学]